Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Sep 09, 2023 1:07pm

132 Views

Post# 35627706

RE:RE:A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

ONCY doesn't have the expertise to run two PIII trials. The investment community recognize this and will punish the sp if they attempt to go alone. They have relied exclusively on 3rd parties to define how pela works. Trying to run two PIII trials would be the worse possible of option.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project